Skip to main content

Table 5 Visual acuity and central retinal thickness outcome by response to ranibizumab and genotypes

From: Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects

   Responders (n = 54) Non-responders (n = 91)
ARMS2 rs10490924   GG (n = 16) GT (n = 22) TT (n = 16) P c GG (n = 5) GT (n = 35) TT (n = 51) P c
 Age   66.68 ± 7.88 68.77 ± 6.97 69.38 ± 3.70 0.469 65.80 ± 5.81 71.34 ± 8.12 68.71 ± 8.07 0.187
 Smoking   5 (31.3) 8 (36.4) 2 (12.5) 0.251 2 (40.0) 16 (45.7) 17 (33.3) 0.509
 Mean BCVA (logMAR)a Baseline 0.58 ± 0.27 0.67 ± 0.27 0.72 ± 0.28 0.328b 0.64 ± 0.35 0.49 ± 0.26 0.51 ± 0.22 0.509b
3 months 0.51 ± 0.25 0.54 ± 0.27 0.67 ± 0.36 0.253 0.82 ± 0.26 0.61 ± 0.25 0.59 ± 0.23 0.191b
6 months 0.33 ± 0.19 0.48 ± 0.26 0.45 ± 0.22 0.119b 0.82 ± 0.26 0.65 ± 0.28 0.67 ± 0.28 0.420b
 Mean CRT (μM)a Baseline 432.7 ± 107.73 490.5 ± 159.19 514.1 ± 180.79 0.307 370.2 ± 192.43 324.7 ± 86.96 324.1 ± 73.19 0.525
3 months 327.1 ± 88.53 367.3 ± 138.55 342.5 ± 103.94 0.562 397.8 ± 320.3 347.8 ± 128.34 357.1 ± 90.37 0.406b
6 months 307.7 ± 85.37 323.6 ± 103.78 332.3 ± 108.36 0.78 374.4 ± 269.59 348.7 ± 143.92 421.4 ± 127.03 0.072
 Changes in BCVA (logMAR)a 3 months − 0.07 ± 0.13 − 0.13 ± 0.22 − 0.05 ± 0.23 0.462b 0.18 ± 0.30 0.12 ± 0.21 0.08 ± 0.17 0.651b
6 months − 0.24 ± 0.16 − 0.19 ± 0.24 − 0.26 ± 0.23 0.593 0.18 ± 0.30 0.16 ± 0.21 0.15 ± 0.24 0.960b
 Changes in CRT (μM)a 3 months − 105.6 ± 59.04 − 123.2 ± 122.81 − 171.6 ± 188.21 0.349 27.6 ± 136.82 23.1 ± 92.01 33.0 ± 72.25 0.865
6 months − 125.0 ± 52.98 − 166.8 ± 135.36 − 181.8 ± 176.76 0.454 4.2 ± 85.65 23.9 ± 94.53 97.3 ± 128.36 0.009*
 Logistic regressiond Co-dominant e P < 0.001*, OR = 3.15, 95% CI (1.75–5.67)     
HTRA1 rs11200638   GG (n = 15) GA (n = 21) AA (n = 18)   GG (n = 4) GA (n = 26) AA (n = 61)  
 Age   66.53 ± 8.13 68.95 ± 7.07 69.11 ± 3.66 0.455 63.75 ± 4.11 70.62 ± 8.39 69.49 ± 8.04 0.286
 Smoking   4 (26.7) 9 (42.9) 2 (11.1) 0.087 2 (50.0) 13 (50.0) 20 (32.8) 0.284
 Mean BCVA (logMAR)a Baseline 0.55 ± 0.25 0.69 ± 0.28 0.69 ± 0.27 0.192b 0.73 ± 0.34 0.55 ± 0.26 0.48 ± 0.22 0.180b
3 months 0.49 ± 0.25 0.58 ± 0.29 0.62 ± 0.33 0.521 0.90 ± 0.20 0.63 ± 0.25 0.58 ± 0.23 0.034b*
6 months 0.32 ± 0.19 0.48 ± 0.26 0.46 ± 0.22 0.059b 0.90 ± 0.20 0.67 ± 0.25 0.65 ± 0.29 0.191b
 Mean CRT (μM)a Baseline 444.7 ± 99.74 487.1 ± 168.15 502.1 ± 174.90 0.556 382.0 ± 220.09 318.8 ± 80.19 326.7 ± 77.79 0.406
3 months 332.4 ± 88.99 380.5 ± 141.31 323.2 ± 94.33 0.251 417.5 ± 366.34 339.7 ± 116.68 358.6 ± 102.01 0.519b
6 months 313.4 ± 85.14 333.1 ± 109.14 314.6 ± 100.66 0.794 388.3 ± 309.23 348.7 ± 146.94 408.9 ± 130.38 0.212
 Changes in BCVA (logMAR)a 3 months − 0.05 ± 0.10 − 0.12 ± 0.23 − 0.08 ± 0.23 0.735b 0.18 ± 0.36 0.08 ± 0.20 0.10 ± 0.18 0.870b
6 months − 0.23 ± 0.16 − 0.22 ± 0.25 − 0.24 ± 0.22 0.945 0.18 ± 0.35 0.12 ± 0.18 0.17 ± 0.24 0.664b
 Changes in CRT (μM)a 3 months − 112.3 ± 54.30 − 106.6 ± 115.37 − 178.9 ± 183.41 0.191 35.5 ± 156.67 20.9 ± 73.19 31.9 ± 83.25 0.846
6 months − 131.3 ± 48.17 − 154.0 ± 135.01 − 187.5 ± 171.50 0.474 6.3 ± 98.75 29.9 ± 91.8 82.3 ± 128.03 0.107
 Logistic regressiond Recessivee P < 0.001*, OR = 4.42, 95% CI (2.11–9.25)     
  1. CRT central retinal thickness, BCVA best-corrected visual acuity, OR odds ratio, CI confidence interval
  2. *Significant P value, P < 0.05
  3. aData presented as mean ± standard deviation (SD)
  4. bKruskal-Wallis test
  5. cOne-way ANOVA
  6. dAdjusted for age and gender
  7. eRegression model with the least P value